Market research
ADMA ADMA Biologics Inc
NASDAQ USD Healthcare
Latest close
Loading market data…
Test a moving-average rule with historical data.
- Market cap
- 2B
- P/E ratio
- 14.06
- Analyst target
- 17
- Dividend yield
- Not available
- Beta
- 0.77
Profile
Company facts
- Exchange
- NASDAQ
- Currency
- USD
- Sector
- Healthcare
- Industry
- Biotechnology
- ISIN
- US0008991046
- Market cap
- 2B
- P/E ratio
- 14.06
- Analyst target
- 17
- Dividend yield
- Not available
- Beta
- 0.77
About
About ADMA Biologics Inc
ADMA Biologics, Inc., a biopharmaceutical company, develops, manufactures, and markets specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company operates through ADMA BioManufacturing and Plasma Collection Centers segments. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB, a human polyclonal antibody product for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B. It also develops a pipeline of plasma-derived therapeutics comprising products related to the methods of treatment and prevention of S. pneumonia infection for an immunoglobulin. In addition, the company operates source plasma collection facilities. The company sells its products through independent distributors, drug wholesalers, specialty pharmacies, and other alternate site providers. ADMA Biologics, Inc. was incorporated in 2004 and is headquartered in Ramsey, New Jersey.
Visit company websiteCommunity
Investor discussion
1 comment
Sign in to join the ADMA discussion.
5 years, 4 months ago
ADMA Biologics, Inc is currently in a long term downtrend where the price is trading 26.0% below its 200 day moving average.
From a valuation standpoint, the stock is 99.7% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 3.7.
ADMA Biologics, Inc's total revenue rose by 36.8% to $14M since the same quarter in the previous year.
Its net income has increased by 99.9% to $-19K since the same quarter in the previous year.
Finally, its free cash flow fell by 34.0% to $-36M since the same quarter in the previous year.
Based on the above factors, ADMA Biologics, Inc gets an overall score of 3/5.